The investigational chemoprotection drug ALRN-6924, a dual inhibitor of MDMX and MDM2, shows potential for radioprotection

被引：1
|
作者：
Annis, Allen
Sutton, David
Aivado, Manuel
Vukovic, Vojislav
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2021年 / 20卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-21-P211
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P211
引用
收藏
页数：2
相关论文
共 32 条
  • [1] The investigational peptide drug ALRN-6924, a dual inhibitor of MDMX and MDM2, is an effective myelopreservation agent
    Carvajal, Luis A.
    Sutton, David
    Mounir, Mariam
    McClanaghan, Joseph
    Guerlavais, Vincent
    Aivado, Manuel
    Vukovic, Vojislav
    Annis, Allen
    [J]. MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [2] ALRN-6924 IS A DUAL MDMX/MDM2 INHIBITOR AND CAN PROTECT THE BONE MARROW OF CANCER PATIENTS TREATED WITH CHEMOTHERAPY
    Vukovic, Vojislav
    Annis, Allen
    Ferrari, Dora
    Aivado, Manuel
    [J]. EXPERIMENTAL HEMATOLOGY, 2021, 100 : S61 - S61
  • [3] Prevention of Chemotherapy-induced Myelosuppression in SCLC patients treated with the Dual MDMX/MDM2 Inhibitor ALRN-6924
    Andric, Z.
    Ceric, T.
    Stanetic, M.
    Rancic, M.
    Jakopovic, M.
    Aix, S. Ponce
    Ramlau, R.
    Smit, E.
    Ulanska, M.
    Caldwell, C.
    Ferrari, D.
    Annis, A.
    Vukovic, V.
    Zaric, B.
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 138 : S5 - S5
  • [4] A phase Ib/II study of the dual MDMX/MDM2 inhibitor, ALRN-6924, for the prevention of chemotherapy-induced myelosuppression
    Andric, Z.
    Ceric, T.
    Rancic, M.
    Jakopovic, M.
    Aix, S. Ponce
    Ramlau, R.
    Ulanska, M.
    Caldwell, C.
    Ferrari, D.
    Annis, A.
    Vukovic, V.
    Zaric, B.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1166 - S1166
  • [5] A phase I pharmacology study of the dual MDMX/MDM2 inhibitor, ALRN 6924, in healthy volunteers
    Voors-Pette, C.
    Aalders, W.
    Brill, M.
    Ferrari, D.
    Annis, A.
    Steidl, U.
    Aivado, M.
    Vukovic, V.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1222 - S1223
  • [6] A Phase I multicenter trial of the dual MDM2/MDMX inhibitor ALRN-6924 in children and young adults with relapsed/refractory pediatric cancers
    Shulman, David S.
    Vo, Kieuhoa T.
    Fox, Elizabeth
    Muscal, Jodi A.
    Walensky, Loren D.
    Pikman, Yana
    Stegmaier, Kimberly
    Church, Alanna
    Crompton, Brian D.
    Place, Andrew E.
    Chi, Susan N.
    O'Neill, Allison F.
    Kamihara, Junne
    Ezrre, Suzanne
    Carlowicz, Cecilia
    Pinchasik, Dawn
    Al-Sayegh, Hasan
    Ma, Clement
    London, Wendy B.
    DuBois, Steven G.
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [7] ALRN-6924, a dual inhibitor of MDMX and MDM2, protects human scalp hair follicles and their epithelial stem cells from paclitaxel-induced toxicity
    Gherardini, J.
    Annis, A. D.
    Cheret, J.
    Aivado, M.
    Paus, R.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : B33 - B33
  • [8] Harnessing the anticancer activity of the stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, using rational combination strategies for breast cancer and other malignancies
    Annis, A.
    Ren, J. G.
    Carvajal, L. A.
    Santiago, S.
    Narasimhan, N.
    Sutton, D.
    Pairawan, S. S.
    Guerlavais, V.
    Meric-Bernstam, F.
    Aivado, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 103 : E143 - E144
  • [9] Pseudoprogression (PsP) in Patients with Peripheral T-Cell Lymphoma (PTCL) Treated with the Novel Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2
    Shustov, Andrei R.
    Mehta, Amitkumar
    Sokol, Lubomir
    Carvajal, Luis A.
    Guerlavais, Vincent
    Samant, Manoj
    Narasimhan, Narayana
    Sutton, David
    Annis, D. Allen
    Pinchasik, Dawn
    Aivado, Manuel
    Korn, Ronald
    [J]. BLOOD, 2018, 132
  • [10] Alrn-6924, a Dual Inhibitor of MDMX and MDM2, Transiently Induces Cell Cycle Arrest in Bone Marrow and Prevents Toxicity in Mouse Models of Acute Radiation Injury
    Annis, Allen
    Sutton, David
    Aivado, Manuel
    Vukovic, Vojislav
    [J]. BLOOD, 2021, 138
1234